In a large meta-analysis, circulating protein levels of severe COVID patients along with many thousands of genomic datasets leads to an exciting discovery: a mutation in a gene called FAS that turns it into a non-membrane-bound, soluble form, interrupting normal immune function. In addition, an on-market chemotherapeutic drug has been shown to lower soluble FAS, … Read more
A new post that presents the concepts underlying combining 30 years of genomic research with the proteins in circulation to determine not only disease risk but the cause of disease.
With a robust collection of 500,000 individuals, the UK Biobank will succeed in its mission to study the determinants of disease through genetics and proteomics combined with extensive electronic health records and ongoing assessments What the UK Biobank is and its current status The UK Biobank (abbreviated UKB or UKBB) began in 2006 as a … Read more
An economical and scalable benchtop instrument bringing multiplex protein assays to individual laboratories or centralized core facilities The Olink original offering: 96-plex on the Fluidigm Biomark Olink started its commercial laboratory in the Boston area in 2016, based upon the Proximity Extension Assay technology and method published in a 2014 PLoS One paper entitled “Homogenous … Read more
At #AGBT19 there is a palpable movement from dissociated single cells to single cells in situ Every year at the Advances of Genome Biology and Technology you can see what the future holds. When long-read sequencing was introduced in 2011, people here at AGBT19 are still talking about that Pacific Biosciences fireworks display on the … Read more
Can a graphene biosensor company like Cardea Biosciences play a role in making P4 medicine (predictive, preventive, personalized and participatory medicine) a reality? Lee Hood’s vision for P4 medicine It was about six years ago I attended a Personalized Healthcare conference at Virginia Commonwealth University in Richmond Virginia, where Leroy Hood of the Institute of … Read more